Alberto Lleó

Dr. Alberto Lleó is the director of the Neurology Department at Hospital de la Santa Creu i Sant Pau.

After obtaining his Medical degree from the University of Barcelona, he completed his specialization in Neurology at Hospital de la Santa Creu i Sant Pau in 2000. Two years later, he obtained his PhD in Medicine at the University of Barcelona. After that, he continued his education with a clinical and basic research fellowship on memory and movement disorders at the Massachusetts General Hospital, Boston (2002-2004) where he combined clinical and research tasks.

In his professional career, Dr. Alberto Lleó has combined his clinical activity with translational research projects in the field of dementias, with a specific focus on the molecular bases of the disease and biomarker development. Some of his main contributions are the discovery of new genetic alterations in Alzheimer’s disease, the study of the gamma-secretase complex, and the assessment of new chemical biomarkers for Alzheimer’s disease and frontotemporal dementia.

Today, Dr. Alberto Lleó runs a translational group, leads many projects funded by public and private agencies, and collaborates regularly with numerous national and international research groups. He also coordinates the Alzheimer program of CIBERNED (Center for Networked Biomedical Research in Neurodegenerative Diseases). To date, he has authored more than 20 book chapters and over 150 publications in international journals, and his contributions have been awarded by the Spanish Society of Neurology.

Recent Publications

  1. Synaptic oligomeric tau in Alzheimer's disease - A potential culprit in the spread of tau pathology through the brain. Colom-Cadena, M, Davies, C, Sirisi, S et al. Neuron 2023

  2. Multifocal Transcranial Direct Current Stimulation in Primary Progressive Aphasia Does Not Provide a Clinical Benefit Over Speech Therapy. Borrego-Écija, S, Montagut, N, Martín-Trias, P et al. J Alzheimers Dis 2023

  3. Correction: Plasma glial fibrillary acidic protein and neurofilament light chain for the diagnostic and prognostic evaluation of frontotemporal dementia. Zhu, N, Santos-Santos, M, Illán-Gala, I et al. Transl Neurodegener 2023

  4. CSF proteome profiling across the Alzheimer's disease spectrum reflects the multifactorial nature of the disease and identifies specific biomarker panels. Del Campo, M, Peeters, CFW, Johnson, ECB et al. Nat Aging 2022

  5. Effects of storage conditions on the stability of blood-based markers for the diagnosis of Alzheimer's disease. Mansilla, A, Canyelles, M, Ferrer, R et al. Clin Chem Lab Med 2023

  6. Association of biological sex with clinical outcomes and biomarkers of Alzheimer's disease in adults with Down syndrome. Iulita, MF, Bejanin, A, Vilaplana, E et al. Brain Commun 2023

  7. Cross-sectional versus longitudinal cognitive assessments for the diagnosis of symptomatic Alzheimer's disease in adults with Down syndrome. Videla, L, Benejam, B, Carmona-Iragui, M et al. Alzheimers Dement 2023

  8. Basal forebrain atrophy along the Alzheimer's disease continuum in adults with Down syndrome. Rozalem Aranha, M, Iulita, MF, Montal, V et al. Alzheimers Dement 2023

  9. Plasma and cerebrospinal fluid glial fibrillary acidic protein levels in adults with Down syndrome: a longitudinal cohort study. Montoliu-Gaya, L, Alcolea, D, Ashton, NJ et al. EBioMedicine 2023

  10. Blood Biomarkers in Neurodegenerative Diseases: Implications for the Clinical Neurologist. Alcolea, D, Beeri, MS, Rojas, JC et al. Neurology 2023

  11. Multiomics profiling of human plasma and cerebrospinal fluid reveals ATN-derived networks and highlights causal links in Alzheimer's disease. Shi, L, Xu, J, Green, R et al. Alzheimers Dement 2023

  12. Author Correction: Common variants in Alzheimer's disease and risk stratification by polygenic risk scores. de Rojas, I, Moreno-Grau, S, Tesi, N et al. Nat Commun 2023

  13. Correction: Cortical microstructure in primary progressive aphasia: a multicenter study. Illán-Gala, I, Montal, V, Borrego-Écija, S et al. Alzheimers Res Ther 2023

  14. Amyloid precursor protein 𝛽CTF accumulates in synapses in sporadic and genetic forms of Alzheimer's disease. Ferrer-Raventós, P, Puertollano-Martín, D, Querol-Vilaseca, M et al. Neuropathol Appl Neurobiol 2023

  15. Predicting AT(N) pathologies in Alzheimer's disease from blood-based proteomic data using neural networks. Zhang, Y, Ghose, U, Buckley, NJ et al. Front Aging Neurosci 2022

Search PubMed